Immunovant (IMVT) Short term Debt (2019 - 2023)

Immunovant has reported Short term Debt for 4 years, with the latest figure at $350000.0 in Q1 2023.

• For the quarter ending Q1 2023, Short term Debt rose 104.68% year-over-year to $350000.0; the trailing twelve-month figure through Mar 2023 stood at $350000.0 (up 104.68% YoY), and the FY2023 full-year result was $350000.0, up 104.68% from the prior year.
• Short term Debt for Q1 2023 stood at $350000.0, up from $171000.0 in the prior quarter.
• The five-year high for Short term Debt was $5.0 million in Q2 2019, with the low at $58000.0 in Q1 2019.
• Historically, Short term Debt has averaged $1.7 million across 4 years, with a median of $350000.0 in 2023.
• The largest YoY upside for Short term Debt was 5400.0% in 2020 against a maximum downside of 94.64% in 2020.
• Immunovant's Short term Debt stood at $3.1 million in 2019, then sank by 95.72% to $134000.0 in 2020, then increased by 27.61% to $171000.0 in 2022, then surged by 104.68% to $350000.0 in 2023.
• The last three Short term Debt figures came in at $350000.0 (Q1 2023), $171000.0 (Q1 2022), and $134000.0 (Q3 2020), per Business Quant data.